These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 22897138

  • 1. Fractalkine and its receptor (CX3CR1) in patients with stable coronary artery disease and diabetes mellitus.
    Njerve IU, Pettersen AÅ, Opstad TB, Arnesen H, Seljeflot I.
    Metab Syndr Relat Disord; 2012 Dec; 10(6):400-6. PubMed ID: 22897138
    [Abstract] [Full Text] [Related]

  • 2. Chemokine CX3CL1 and its receptor CX3CR1 are associated with human atherosclerotic lesion volnerability.
    Zhang X, Feng X, Cai W, Liu T, Liang Z, Sun Y, Yan C, Han Y.
    Thromb Res; 2015 Jun; 135(6):1147-53. PubMed ID: 25845619
    [Abstract] [Full Text] [Related]

  • 3. Hypertrophy of the ligament flavum in degenerative lumbar stenosis associated with the increased expression of fractalkine (CX3CL1)/CX3CR1 chemokine.
    Oh IS, Suh DW, Ha KY.
    Connect Tissue Res; 2013 Jun; 54(6):380-5. PubMed ID: 24060055
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Fractalkine is a novel human adipochemokine associated with type 2 diabetes.
    Shah R, Hinkle CC, Ferguson JF, Mehta NN, Li M, Qu L, Lu Y, Putt ME, Ahima RS, Reilly MP.
    Diabetes; 2011 May; 60(5):1512-8. PubMed ID: 21525510
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Characterization of fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease.
    Wong BW, Wong D, McManus BM.
    Cardiovasc Pathol; 2002 May; 11(6):332-8. PubMed ID: 12459434
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Characterisation of fractalkine/CX3CL1 and fractalkine receptor (CX3CR1) expression in abdominal aortic aneurysm disease.
    Patel A, Jagadesham VP, Porter KE, Scott DJ, Carding SR.
    Eur J Vasc Endovasc Surg; 2008 Jul; 36(1):20-7. PubMed ID: 18296082
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Polymorphisms of Fractalkine receptor CX3CR1 and plasma levels of its ligand CX3CL1 in colorectal cancer patients.
    Dimberg J, Dienus O, Löfgren S, Hugander A, Wågsäter D.
    Int J Colorectal Dis; 2007 Oct; 22(10):1195-200. PubMed ID: 17611763
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Role of fractalkine in the pathogenesis of primary Sjögren syndrome: increased serum levels of fractalkine, its expression in labial salivary glands, and the association with clinical manifestations.
    Lee JH, Kwok SK, Jung SM, Lee J, Lee JS, Baek SY, Kim EK, Ju JH, Park SH, Kim HY.
    J Rheumatol; 2014 Dec; 41(12):2425-38. PubMed ID: 25320221
    [Abstract] [Full Text] [Related]

  • 18. Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3CL1).
    Lucas AD, Bursill C, Guzik TJ, Sadowski J, Channon KM, Greaves DR.
    Circulation; 2003 Nov 18; 108(20):2498-504. PubMed ID: 14581400
    [Abstract] [Full Text] [Related]

  • 19. Association of hydrogen sulfide with alterations of monocyte chemokine receptors, CCR2 and CX3CR1 in patients with coronary artery disease.
    Gao L, Xu Z, Yin Z, Chen K, Wang C, Zhang H.
    Inflamm Res; 2015 Aug 18; 64(8):627-35. PubMed ID: 26123579
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.